Scientific Reviews
Product Guides
Blogs
Topics
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!2025-02-06
15 Results for "
mouse sarcoma cell
" in MedChemExpress (MCE) Product Catalog:
Products (15)
15 Results for "mouse sarcoma cell" in MCE Product Catalog:
4
4 Cited Publications
Cat. No.: HY-P1408
CAS No.: 404882-00-4
1
Category:
Flavonols other families Flavonoids Monophenols Phenols Plants Disease Research Fields Inflammation/Immunology
Target:
Cat. No.: HY-N0891
CAS No.: 115810-12-3
Synonyms: Tubeimoside-B
Cat. No.: HY-176798
CAS No.: 1964516-64-0
Research Areas:
NCI-006 is an orally active lactate dehydrogenase (LDH) inhibitor (LDHA IC50 = 0.06 μM; LDHB IC50 = 0.03 μM). NCI-006 inhibits intratumoral LDH activity, lactate production, and tumor growth in a mouse pancreatic cancer model. NCI-006 inhibits glycolysis and induces apoptosis in vitro. NCI-006 enhances the radiosensitivity of glycolytic tumor cell lines while sparing non-glycolytic/normal cells (1522, skin fibroblasts) in combination with ionizing radiation (IR). NCI-006 exhibits synergistic antitumor effects in combination with IACS-010759 (HY-112037) against colorectal and gastric cancers. NCI-006 targets glycolysis by inhibiting lactate dehydrogenase impairs tumor growth in an Ewing sarcoma model .
Category:
Target:
Cat. No.: HY-162239
Target:
Research Areas:
Anticancer agent 187 (Compound 4) is an anticancer agent that can target sarcoma cells in tumor-bearing mouse models. Anticancer agent 187 exhibits cytotoxic activity against HepG2, Caco2, and MCF-7 cells .
Cat. No.: HY-123371
CAS No.: 68160-71-4
Ro 07-1902 is a potent antitumor synergist . Ro 07-1902 enhances the antitumor effects of CCNU (HY-13669), Chlorambucil (HY-13593) and Cyclophosphamide (HY-17420). Ro 07-1902 exhibits no single-agent cytotoxicity and does not delay tumor growth. Ro 07-1902 can be used in research related to various cancers .
Cat. No.: HY-125322
CAS No.: 144860-69-5
Reveromycin C is a polyketide originally isolated from Streptomyces that has antifungal activity against C. albicans (MICs=2.0 and >500 μg/mL at pH 3 and 7.4, respectively). Reveromycin C inhibits EGF-induced mitogenic activity in the Balb/MK mouse epidermal cell line. It also reverses the morphology of sarcoma-virus-transformed NRK rat kidney cells (EC50=1.58 μg/mL) and inhibits proliferation of KB cells and K562 human chronic myelogenous leukemia cells (IC50=2.0 μg/mL for both).
Cat. No.: HY-121365
CAS No.: 71522-58-2
Forphenicinol is an immunomodulator and a derivative of the bacterial metabolite forphenicine. It increases the phagocytosis of yeast by peritoneal macrophages isolated from thioglycolate-stimulated mice. Forphenicinol (100 μg/animal) prevents cyclophosphamide-induced suppression of delayed-type hypersensitivity (DTH), as well as enhances DTH in response to the hapten oxazolone or sheep red blood cells in mice. It enhances the bactericidal activity of macrophages against P. aeruginosa in mice when administered at a dose of 0.5 mg/kg.2 Forphenicinol (15.6-1,000 μg/animal) increases survival in a mouse model of P. aeruginosa infection. It also inhibits tumor growth in S180 sarcoma and IMC carcinoma mouse xenograft models when administered at doses ranging from 0.05 to 5 mg/kg per day.
Cat. No.: HY-P991754
Target:
Research Areas:
Anti-Mouse TREM2 Antibody (178) is an antibody targeting mouse TREM2, which blocks the binding of ligands to TREM2 and inhibits TREM2-mediated signaling pathways. Anti-Mouse TREM2 Antibody (178) inhibits the tumor growth of MCA/1956 sarcoma in mice. Anti-Mouse TREM2 Antibody (178) enhances IFNγ production by intratumoral CD8 + T cells and TNFα production by intratumoral CD4 + T cells. Anti-Mouse TREM2 Antibody (178) can be used in the research of sarcoma, colorectal cancer and breast tumors. The recommended isotype control is Rat IgG2a kappa, Isotype Control (HY-P990679) .
Cat. No.: HY-182082
Target:
Research Areas:
XYD270 is an orally active BRD9 PROTAC degrader. XYD270 inhibits the proliferation of cancer cells. XYD270 suppresses tumor growth in a mouse model of acute myeloid leukemia. XYD270 can be used in research related to synovial sarcoma and acute myeloid leukemia .
Cat. No.: HY-183858
CAS No.: 1964516-59-3
Target:
Research Areas:
NCATS-SM1440 is a glycolysis inhibitor and metabolic regulator that targets LDHA and LDHB (IC50=0.06 μM and 0.03 μM, respectively). Upon binding to LDHA, NCATS-SM1440 blocks the glycolysis pathway and reduces lactate production. NCATS-SM1440 drives the shift of pyruvate metabolism toward mitochondrial metabolism, effectively disrupting the dependence of cancer cells on aerobic glycolysis. NCATS-SM1440 can be widely used in research related to cancer, Ewing's sarcoma, and other related conditions .
Cat. No.: HY-159803
CAS No.: 128201-92-3
Synonyms: 6-O-(3-Ethoxypropionyl)-3',4'-O-exo-benzylidenechartreusin
Target:
Research Areas:
IST-622 (6-O-(3-Ethoxypropionyl)-3',4'-O-exo-benzylidenechartreusin) is an anti-tumor agent with significant growth inhibitory activity. IST-622 exhibits significant anti-tumor effects against a variety of mouse tumors such as P388 and L1210 leukemias, B16 melanoma, Lewis lung carcinoma, Colon 26 and Colon 38 adenocarcinomas, and M5076 reticulum cell sarcoma. IST-622 was orally administered and the results showed efficacy in different tumor types. In addition, IST-622 provided significant inhibitory effects against two human tumor xenograft models: large cell lung carcinoma (Lu-116) and gastric adenocarcinoma (St-4). IST-622 also exhibited significant growth inhibitory activity against P388 leukemia in vitro, with a half inhibitory concentration (IC50) more than 20 times lower than CT .
Cat. No.: HY-184266
CAS No.: 2926699-71-8
Synonyms: ONO-6428513
Target:
Research Areas:
GCLCi0 (ONO-6428513) is a glutamate-cysteine ligase catalytic subunit (GCLC) inhibitor and ferroptosis inducer that blocks the rate-limiting step of glutathione synthesis and exerts anti-tumor activity. GCLCi0 specifically targets SMARCB1-deficient cancer cells, induces reactive oxygen species production and lipid peroxidation. In addition, GCLCi0 shows a significant synergistic effect with SLC7A11 inhibitors and Telaglenastat (HY-12248). GCLCi0 can be used in the research of smarcb1-deficient malignant rhabdoid tumors and smarcb1-deficient epithelioid sarcomas .
Cat. No.: HY-184267
CAS No.: 2926699-78-5
Synonyms: ONO-7068506
Research Areas:
GCLCi1 is an orally active glutamate-cysteine ligase catalytic subunit (GCLC) inhibitor and ferroptosis inducer. GCLCi1 blocks the rate-limiting step of glutathione synthesis, leading to GSH depletion, elevated reactive oxygen species and lipid peroxidation. GCLCi1 exhibits high selectivity for SMARCB1 -deficient cancer cells and possesses anti-tumor activity. In addition, the combination of GCLCi1 with SLC7A11 inhibitors and Telaglenastat (HY-12248) produces a synergistic effect, which can be used for the research of smarcb1-deficient malignant rhabdoid tumors and smarcb1-deficient epithelioid sarcomas .
- 1
-
-
Protocols
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!A suitable model is crucial in drug screening experiments. Organs can mimic the three-dimensional functional structure of internal organs, have similar spatial organization to corresponding organs, maintain some key characteristics, and reproduce some physiological functions. They are widely used for modeling and personalized drug screening physiological functions.2025-02-06
